Raquel Torres-Iglesias

Raquel Torres-Iglesias

Auto-generated profile, based on publicly available information

Raquel Torres-Iglesias

HHT Unit, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain; Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain; Internal Medicine Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2023 in Medicina
Verified
Journal Article
Open access
PDF file
BVBernat Villanueva
Bernat Villanueva
AIAdriana Iriarte
Adriana Iriarte
RTRaquel Torres-Iglesias
Raquel Torres-Iglesias
MMMiriam Muñoz
Miriam Muñoz
PSPau Cerdà Serra
Pau Cerdà Serra
ARAntoni Riera-Mestre
Antoni Riera-Mestre
Herein, we present the first described hereditary hemorrhagic telangiectasia (HHT) patient treated with aflibercept for severe GI involvement after tachyphylaxis to bevacizumab, with promising results. HHT is a rare genetic disease characterized by systemic vascular malformations. Gastrointestinal telangiectasia is one of the major involvements that can produce chronic severe iron-deficiency anemia. Nowadays, support treatment with iron replacement therapy, red blood cell transfusions, and antiangiogenic drugs—mainly bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF)—are the main therapeutic options for this complication. The evidence of alternative drugs in patients with failure to this approach, such as tachyphylaxis to bevacizumab, is scarce. Aflibercept is a VEGF inhibitor with antiangiogenic properties approved for the treatment of different types of cancer and ocular neovascularization diseases.

7 January 2026 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
RTR Torres-Iglesias
R Torres-Iglesias
LTLuis Teruel
Luis Teruel
MSMa Sánchez-Corral
Ma Sánchez-Corral
PSPau Cerdà Serra
Pau Cerdà Serra
BVB Villanueva
B Villanueva
ARAntoni Riera-Mestre
Antoni Riera-Mestre

22 March 2023 in Genes
Verified
Journal Article
Open access
PDF file
CACinthia Aguilera
Cinthia Aguilera
APAriadna Padró-Miquel
Ariadna Padró-Miquel
AEAnna Esteve-Garcia
Anna Esteve-Garcia
PSPau Cerdà Serra
Pau Cerdà Serra
RTRaquel Torres-Iglesias
Raquel Torres-Iglesias
ARAntoni Riera-Mestre
Antoni Riera-Mestre
Background: Hereditary hemorrhagic telangiectasia (HHT) is a rare vascular disease inherited in an autosomal dominant manner. Disease-causing variants in endoglin (ENG) and activin A receptor type II-like 1 (ACVRL1) genes are detected in more than 90% of the patients undergoing molecular testing. The identification of variants of unknown significance is often seen as a challenge in clinical practice that makes family screening and genetic counseling difficult. Here, we show that the implementation of cDNA analysis to assess the effect of splice site variants on mRNA splicing is a powerful tool. Methods: Gene panel sequencing of genes associated with HHT and other arteriovenous malformation-related syndromes was performed. To evaluate the effect of the splice site variants, cDNA analysis of ENG and ACVRL1 genes was carried out. Results: three novel splice site variants were identified in ENG (c.68-2A > T and c.1311+4_1311+8del) and ACVLR1 (c.526-6C > G) genes correspondingly in three individuals with HHT that met ≥ 3 Curaçao criteria. All three variants led to an aberrant splicing inducing exon skipping (ENG:c.68-2A > T and ACVRL1:c.526-6C > G) or intron retention (ENG:c.1311+4_1311+8del) allowing the confirmation of the predicted effect on splicing and the reclassification from unknown significance to pathogenic/likely pathogenic of two of them. Conclusions: RNA analysis should be performed to assess and/or confirm the impact of variants on splicing. The molecular diagnosis of HHT patients is crucial to allow family screening and accurate genetic counseling. A multidisciplinary approach including clinicians and geneticists is crucial when dealing with patients with rare diseases.

23 September 2020 in medRxiv
Verified
Preprint
Open access
PDF file
PSPau Cerdà Serra
Pau Cerdà Serra
JRJesús Ribas
Jesús Ribas
AIAdriana Iriarte
Adriana Iriarte
JMJosé María Mora-Luján
José María Mora-Luján
RTRaquel Torres
Raquel Torres
ARAntoni Riera-Mestre
Antoni Riera-Mestre
Background: A higher incidence of thrombotic events, mainly pulmonary embolism (PE), has been reported in hospitalized patients with COVID-19. The main objective was to assess clinical and weekly laboratory differences in hospitalized COVID-19 patients according to occurrence of PE. Methods: This retrospective study included all consecutive patients hospitalized with COVID-19 who underwent a computed tomography (CT) angiography for PE clinical suspicion. Clinical data and median blood test results distributed into weekly periods from COVID-19 symptoms onset were compared between PE and non-PE patients. Results: Ninety-two patients were included, 29 (32%) had PE. PE patients were younger (63.9 (SD13.7) vs 69.9 (SD12.5) years). Clinical symptoms and COVID-19 CT features were similar in both groups. PE was diagnosed after a mean of 20.0 (SD8.6) days from the onset of COVID-19 symptoms. Corticosteroid boluses were more frequently used in PE patients (62% vs. 43%). Median values [IQR] of D-dimer in PE vs non-PE patients were: week 2 (2010.7 [770.1-11208.9] vs 626.0 [374.0-2382.2]; p =0.04); 3 (3893.1 [1388.2-6694.0] vs 1184.4 [461.8-2447.8]; p =0.03); and 4 (2736.3 [1202.1-8514.1] vs 1129.1 [542.5-2834.6]; p =0.01). Median fold-increase of D-dimer between week 1 and 2 differed between groups (6.64 [3.02-23.05] vs 1.57 [0.64-2.71], p =0.003); ROC curve AUC was 0.879 ( p =0.003) with a sensitivity and specificity for PE of 86% and 80%, respectively. Conclusions: Among hospitalized COVID-19 patients, D-dimer levels are higher at weeks 2, 3 and 4 after COVID-19 symptom onset in patients who develop PE. This difference is more pronounced when the fold increase between weeks 1 and 2 is compared.

24 September 2026 in European Journal of Internal Medicine
Verified
Journal Article
Open access
BVBernat Villanueva
Bernat Villanueva
AFAgnès Figueras
Agnès Figueras
RTRaquel Torres-Iglesias
Raquel Torres-Iglesias
MMMiriam Muñoz
Miriam Muñoz
LSLeticia-Ainhoa Sanz-Astier
Leticia-Ainhoa Sanz-Astier
ARAntoni Riera-Mestre
Antoni Riera-Mestre

7 June 2026 in European Journal of Internal Medicine
Verified
Journal Article
Open access
AEAnna Esteve-Garcia
Anna Esteve-Garcia
IMIrene Madrigal
Irene Madrigal
CACinthia Aguilera
Cinthia Aguilera
CSCristina Sau
Cristina Sau
VAVirginia Aquino
Virginia Aquino
APAriadna Padró-Miquel
Ariadna Padró-Miquel
Hereditary haemorrhagic telangiectasia (HHT) is an autosomal dominant vascular disorder most commonly caused by pathogenic variants in ACVRL1 or ENG. Most pathogenic variants are coding missense, nonsense, splice-site variants, or small insertions/deletions, as well as exon-level deletions or duplications, and are typically detectable by next-generation sequencing (NGS). However, balanced structural rearrangements and deep intronic variants are not reliably detected by standard exome-based approaches and may contribute to genetically unresolved cases. We investigated four unrelated families with clinical features of HHT in whom prior whole exome sequencing (WES) was inconclusive. All affected individuals reported recurrent miscarriages, and further clinical review identified prior karyotype analyses. These cytogenetic findings prompted targeted reanalysis of WES datasets to assess potential disruption of HHT-associated genes. All four families carried an apparently balanced translocation, t(9;12)(p21.2;q13.13). Breakpoint mapping revealed disruption of a CT-rich region within intron 9 of ACVRL1, a known mutational hotspot. Reanalysis of WES data supported ACVRL1 disruption as the likely pathogenic mechanism. The translocation co-segregated with disease in all families and was absent in unaffected relatives. All carriers fulfilled clinical diagnostic criteria for HHT. A history of recurrent miscarriages emerged as a key clinical clue that prompted cytogenetic investigation and enabled molecular diagnosis. We identify a recurrent translocation, t(9;12)(p21.2;q13.13), that disrupts intron 9 of ACVRL1 and is undetectable by standard exome-based approaches, as a previously unrecognised cause of HHT in genetically unresolved patients. Our findings highlight and support the need to extend genomic testing beyond conventional exome sequencing in unresolved HHT cases.